Petros pharmaceuticals' pivotal statistically significant self selection study shows stronger results with proprietary technology application as part of fda pathway for over-the-counter access for stendra(r) (avanafil)

Utilization of the company's proprietary web app showed improved self-selection utilizing an embedded validated diagnostic questionnaire compared to a live interview furthering the company's efforts to potentially create a first-ever rx-to-otc switch in the ed category new york, ny / accesswire / july 29, 2024 / petros pharmaceuticals, inc. (nasdaq:ptpi) ("petros" or the "company"), a company focused on expanding consumer access to medication through over-the-counter ("otc") drug development programs, today announced results of a subsequent analysis of its pivotal study aimed at facilitating fda-approved otc access of the company's stendra® (avanafil) for consumers. this analysis suggested support for the primary study results and demonstrated improved correct self-selection outcomes resulting from patients using the company's proprietary web app technology and its embedded clinically validated diagnostic tool relative to subsequent verbal interviews that were designed into the study protocol as a form of validation of an ed diagnosis.
PTPI Ratings Summary
PTPI Quant Ranking